{"id":"https://openalex.org/W4361908379","doi":"https://doi.org/10.1158/1078-0432.22450790","title":"Supplementary Figure 1 from \u03b3-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)","display_name":"Supplementary Figure 1 from \u03b3-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361908379","doi":"https://doi.org/10.1158/1078-0432.22450790"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22450790","doi":"https://doi.org/10.1158/1078-0432.22450790","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450790","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.22450790","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103434536","display_name":"Jenny Wu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jenny Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108677744","display_name":"Peter H. Clingen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter H. Clingen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040495838","display_name":"Victoria J. Spanswick","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Victoria J. Spanswick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086908702","display_name":"Maria Mellinas\u2010Gomez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Mellinas-Gomez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060350068","display_name":"Tim Meyer","orcid":"https://orcid.org/0000-0003-0782-8647","observed_orcids":["https://orcid.org/0000-0003-0782-8647","https://orcid.org/0000-0003-2994-9693"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tim Meyer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Igor Puzanov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071360446","display_name":"Duncan Ian Jodrell","orcid":"https://orcid.org/0000-0001-9360-1670","observed_orcids":["https://orcid.org/0000-0001-9360-1670"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Duncan Jodrell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085123244","display_name":"Daniel Hochhauser","orcid":"https://orcid.org/0000-0001-5522-9281","observed_orcids":["https://orcid.org/0000-0001-5522-9281"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Hochhauser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5055669649","display_name":"John Anthony Hartley","orcid":"https://orcid.org/0000-0003-3737-9897","observed_orcids":["https://orcid.org/0000-0003-3737-9897"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John A. Hartley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.4553000032901764,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.4553000032901764,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.21119999885559082,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13105","display_name":"Synthesis and pharmacology of benzodiazepine derivatives","score":0.09279999881982803,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gamma-h2ax-foci","display_name":"\u03b3H2AX foci","score":0.9890000224113464},{"id":"https://openalex.org/keywords/dna-damage","display_name":"DNA damage","score":0.7699999809265137},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.8119999766349792},{"id":"https://openalex.org/keywords/dna-cross-linking-agents","display_name":"DNA cross-linking agents","score":0.9210000038146973},{"id":"https://openalex.org/keywords/sjg-136","display_name":"SJG-136","score":0.984000027179718},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.7269999980926514},{"id":"https://openalex.org/keywords/lymphocytes","display_name":"lymphocytes","score":0.8450000286102295}],"concepts":[{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.6831703782081604},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6616974472999573},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.6133216023445129},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.5930537581443787},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.535333514213562},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.25337159633636475},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22002574801445007},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15555140376091003},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.14861461520195007}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22450790","doi":"https://doi.org/10.1158/1078-0432.22450790","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450790","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22450790.v1","doi":"https://doi.org/10.1158/1078-0432.22450790.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450790.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_-H2AX_Foci_Formation_as_a_Pharmacodynamic_Marker_of_DNA_Damage_Produced_by_DNA_Cross-Linking_Agents_Results_from_2_Phase_I_Clinical_Trials_of_SJG-136_SG2000_/22450790/1/files/39901868.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22450790","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_-H2AX_Foci_Formation_as_a_Pharmacodynamic_Marker_of_DNA_Damage_Produced_by_DNA_Cross-Linking_Agents_Results_from_2_Phase_I_Clinical_Trials_of_SJG-136_SG2000_/22450790","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22450790","doi":"https://doi.org/10.1158/1078-0432.22450790","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450790","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361908379.pdf","grobid_xml":"https://content.openalex.org/works/W4361908379.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7028850227","https://openalex.org/W4361944298","https://openalex.org/W2008638513","https://openalex.org/W1564587970","https://openalex.org/W7033254127","https://openalex.org/W2772739164","https://openalex.org/W2773432115","https://openalex.org/W2773572344","https://openalex.org/W2791849065","https://openalex.org/W2996966995"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"105K,":[3],"Measurement":[4],"of":[5,18,50],"\u03b3-H2AX":[6],"foci":[7],"in":[8,40],"lymphocytes":[9],"(A)":[10],"and":[11,33,36,42],"xenograft":[12],"tumor":[13],"cells":[14,51],"(B)":[15],"following":[16],"treatment":[17],"mice":[19],"i.v.":[20],"with":[21],"either":[22],"0.15":[23],"or":[24,59],"0.3":[25],"mg/kg":[26],"SJG-136.":[27],"Samples":[28],"were":[29],"obtained":[30],"at":[31],"2":[32],"24":[34],"hours":[35],"processed":[37],"as":[38,47],"described":[39],"materials":[41],"methods.":[43],"Data":[44],"are":[45],"expressed":[46],"the":[48],"%":[49],"which":[52],"contain":[53],"0,":[54],"0-5,":[55],"5-10,":[56],"10-15,":[57],"15-20":[58],">20":[60],"foci.":[61]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}